TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3207854
Drug: conventional ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: conventional ibuprofen tablets (2 x 400 mg)
Study: 12708395
Drug: Netilmycin in
Normalized name: Netilmycin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmycin in combination with Cefasolin
Study: 12708395
Drug: Gentamycin in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamycin in combination with Cefasolin
Study: 11885180
Drug: Mobile implants
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile implants at placement
Study: 11885180
Drug: Non-mobile implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-mobile implants at placement
Study: 11885180
Drug: HA-coated implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-coated implants (mobile at placement)
Study: 11885180
Drug: Non-HA-coated implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HA-coated implants (mobile at placement)
Study: 11885180
Drug: HA-coated implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-coated implants (non-mobile at placement)
Study: 11885180
Drug: Non-HA-coated implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HA-coated implants (non-mobile at placement)
Study: 1421911
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of 4 mg/kg of trimethoprim coupled with 17.5 mg/kg of sulphadiazine for 3 days (group 1)
Study: 1421911
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of 4 mg/kg of trimethoprim coupled with 17.5 mg/kg of sulphadiazine for 10 days (group 2)
Study: 3880875
Drug: Allopurinol and
Normalized name: Allopurinol and lesinurad only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol and adenine therapy
Study: 30914464
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP)
Study: 15119909
Drug: Extended-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release carbamazepine (ERC-CBZ)
Study: 10638770
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide pulse therapy (750 mg/m2) for 12 months; concurrent prednisone (10 mg/day)
Study: 10638770
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (2-2.5 mg/kg/day) for 12 months; concurrent prednisone (10 mg/day)
Study: 7781174
Drug: PGE2 vaginal
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 vaginal gel every 12 hours, initial dose of 2 mg followed by two additional doses at 12 hour intervals if not in active labor.
Study: 7781174
Drug: PGE2 vaginal
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 vaginal gel every 6 hours, initial dose of 1 mg followed by 2 mg at 6 hour intervals for a maximum of two additional doses if not in active labor.
Study: 7781174
Drug: PGE2 vaginal
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 vaginal gel every 12 hours
Study: 7781174
Drug: PGE2 vaginal
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 vaginal gel every 6 hours
Study: 1969770
Drug: Succinylcholine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.5 mg.kg‐1 after d-tubocurarine 0.05 mg.kg‐1, intubation after 60 seconds
Study: 1969770
Drug: Succinylcholine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.5 mg.kg‐1 after d-tubocurarine 0.05 mg.kg‐1, intubation after 90 seconds
Study: 1969770
Drug: Vecuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.01 mg.kg‐1 followed by 0.1 mg.kg‐1, intubation after 60 seconds
Study: 1969770
Drug: Vecuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.01 mg.kg‐1 followed by 0.1 mg.kg‐1, intubation after 90 seconds
Study: 23286246
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day palmvitee supplementation
Study: 22120944
Drug: Topical oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical oxytocin gel for seven days
Study: 22120944
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel for seven days
Study: 22120944
Drug: Topical oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical oxytocin gel
Study: 19480654
Drug: Cholecalciferol (vitamin
Normalized name: cholecalciferol (vitamin D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (vitamin D3) 6800 International Units daily for one year
Study: 15496221
Drug: Thioridazine 50
Normalized name: thioridazine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine 50 mg with donepezil 5 mg daily for 2 weeks
Study: 12536625
Drug: Captopril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (1 mg.kg‐1, oral) pretreatment 48 hours before operation
Study: 8024908
Drug: ketorolac 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac 0.75 mg kg‐1 i.v.
Study: 8024908
Drug: morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.1 mg kg‐1 i.v. and metoclopramide 0.15 mg kg‐1
Study: 2811970
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of lithium (serum concentration 0.8 to 1.0 mmol per liter)
Study: 2811970
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of lithium (serum concentration 0.4 to 0.6 mmol per liter)
Study: 825780
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (surgery followed by chemotherapy, second-look laparotomy, and subsequent whole abdominal radiation)
Study: 825780
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (external radiation and single alkylating agent chemotherapy)
Study: 825780
Drug: Triple chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple chemotherapy (cyclophosphamide, dactinomycin, and 5-fluorouracil)
Study: 825780
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent therapy with melphalan
Study: 23718705
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 grams/day for 5 days) with chloroquine (3 days of oral weight-based dosing)
Study: 23718705
Drug: Chloroquine and
Normalized name: chloroquine and proguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine and primaquine (standard doses)
Study: 16700803
Drug: Efalizumab 1
Normalized name: efalizumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab 1 mg/kg SC
Study: 14499423
Drug: THC (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (20 mg)
Study: 14499423
Drug: THC-morphine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC-morphine (20 mg THC + 30 mg morphine)
Study: 14499423
Drug: THC-morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC-morphine
Study: 10682226
Drug: Flurazepam 30
Normalized name: flurazepam 30 mg oral capsule
DrugBank: Flurazepam (DB00690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurazepam 30 mg (active control)
Study: 8104273
Drug: Citalopram 10-20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 10-20 mg daily for 3 weeks
Study: 2868412
Drug: Thiopental (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (30 mg/kg)
Study: 28815639
Drug: VVZ‐149 (0.25-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: VVZ‐149 (0.25-8 mg/kg)
Study: 28815639
Drug: VVZ‐149 (4-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: VVZ‐149 (4-7 mg/kg, twice daily for 3 days)
Study: 28815639
Drug: VVZ‐149 (0.5-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: VVZ‐149 (0.5-8 mg/kg)
Study: 25154831
Drug: High-dose conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose conditioning regimens
Study: 20633184
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication before starting NSAID therapy
Study: 20633184
Drug: Proton-pump inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitors (PPI) therapy
Study: 19127908
Drug: Alprazolam (medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (medication group)
Study: 12856384
Drug: Furosemide gastroretentive
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide gastroretentive dosage form (60 mg)
Study: 9266290
Drug: Immediate-release tablet
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tablet
Study: 8660083
Drug: Ibuprofen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (20 mg/kg/24 hours)
Study: 8660083
Drug: Paracetamol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (50 mg/kg/24 hours)
Study: 8660083
Drug: Both Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both Ibuprofen and Paracetamol
Study: 1853990
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: exclusion and treatment of symptomatic and asymptomatic infected children
Study: 1853990
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: exclusion and treatment of symptomatic infection only
Study: 1853990
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: exclusion and treatment of symptomatic infection, treatment of asymptomatic infection in the center
Study: 29952159
Drug: low‐flu/val: 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: low‐flu/val: 10 mg/20 mg
Study: 27530532
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of oral levofloxacin for 3 days
Study: 27530532
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics for 3 days
Study: 22098272
Drug: Rifaximin 1200
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 1200 mg/d for 4 weeks
Study: 17602085
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 600 mg daily for 26 weeks
Study: 16133127
Drug: Imipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (mean daily dose of 248 mg, dose range 50-450 mg)
Study: 10804906
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin re-uptake inhibitors (SSRIs)
Study: 8679358
Drug: ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 0.15 mg kg‐1
Study: 8679358
Drug: ketamine 0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 0.30 mg kg‐1
Study: 1651993
Drug: Cisplatin-based therapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based therapy
Study: 1651993
Drug: Good PS
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good PS with hemoglobin level >= 11 g/dL and age > 47 years
Study: 1651993
Drug: Hemoglobin level
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin level >= 11.0 g/dL, normal LDH, normal calcium, single metastatic site
Study: 7038553
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg UDPG
Study: 25644279
Drug: ombitasvir 25
Normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg or 150/100 mg for 12 or 24 weeks (subtype 1b)
Study: 25644279
Drug: ombitasvir 25
Normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg for 12 weeks (genotype 2)
Study: 25644279
Drug: ombitasvir 25
Normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg or 150/100 mg (genotype 2)
Study: 24477392
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with 15 sessions at a dosage of 18 J per session over the carpal tunnel area with neutral wrist splint
Study: 24477392
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser therapy with neutral wrist splint
Study: 22468576
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavior therapy for psychosis (CBTp)
Study: 18930200
Drug: Stimulation group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation group (injection of culture medium)
Study: 18930200
Drug: SEET group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEET group (injection of embryo culture supernatant)
Study: 10803800
Drug: tolcapone 100
Normalized name: tolcapone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone 100 mg three times daily
Study: 1443864
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (control inhalation)
Study: 18450803
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of vancomycin (25 mg/kg/day or 15 mg/kg/day in period 1; 30 mg/kg/day or 20 mg/kg/day in period 2)
Study: 12501480
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of cholinesterase plus selective serotonin reuptake inhibitors (SSRIs) (citalopram HBr, 20 mg/day)
Study: 12501480
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of cholinesterase (Donepezil, 5 mg/day)
Study: 3202206
Drug: Propranolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.15 mg/kg)
Study: 2029996
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline, 0.3 ml/kg)
Study: 31013009
Drug: H9N2-specific antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: H9N2-specific antibody detection
Study: 26154851
Drug: 30 mcg
Normalized name: Avonex 30 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mcg of EE + DRSP
Study: 26154851
Drug: 20 mcg
Normalized name: Caverject 20 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg of EE + DRSP
Study: 23642945
Drug: Bee venom
Normalized name: Bee venom
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bee venom acupuncture point injection (0.005% diluted in normal saline, 0.05 ml at each point, twice-weekly for three weeks)
Study: 23642945
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (control group, twice-weekly for three weeks)
Study: 21029347
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily for 4 weeks
Study: 11875051
Drug: MMP1 G‐1607GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMP1 G‐1607GG allele
Study: 11875051
Drug: Haplotypes of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haplotypes of MMP1 G‐1607GG and MMP12 Asn357Ser
Study: 9790160
Drug: Venlafaxine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (37.5 mg daily increasing up to 225 mg daily)
Study: 475947
Drug: Enteric-coated prednisolone
Normalized name: prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated prednisolone tablets (shellac based)
Study: 475947
Drug: Enteric-coated prednisolone
Normalized name: prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated prednisolone tablets (cellulose acetate phthalate based)
Study: 30915462
Drug: Tocilizumab treatment
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab treatment for 52 weeks
Study: 25467560
Drug: Grazoprevir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir (100 mg) plus Elbasvir (20 mg or 50 mg) for 12 weeks without ribavirin
Study: 25467560
Drug: Grazoprevir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir (100 mg) plus Elbasvir (20 mg or 50 mg) for 12 weeks with ribavirin
Study: 25467560
Drug: Grazoprevir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir (100 mg) plus Elbasvir (50 mg) for 8 weeks without ribavirin
Study: 25467560
Drug: Grazoprevir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir (100 mg) plus Elbasvir (50 mg) for 12 weeks
Study: 15553108
Drug: Test tablet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test tablet (levothyroxine sodium tablets 200 microg; Eferox)
Study: 15553108
Drug: Test tablet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test tablet vs Reference tablet
Study: 15553108
Drug: Test tablet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test tablet vs Oral solution
Study: 8305640
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg every 12 h)
Study: 8305640
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg every 12 h) + Aspirin (75 mg/day)
Study: 3329964
Drug: Cisapride 4
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride 4 mg or 8 mg orally three times daily for two successive three-week periods
Study: 3329964
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally three times daily for two successive three-week periods
Study: 30725015
Drug: Self-administered rehabilitation
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered rehabilitation program
Study: 27717635
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 50μg
Study: 27717635
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 100μg
Study: 27717635
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 150μg
Study: 27717635
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac 30mg before leaving the operating room and 15mg every 6h for 24h
Study: 27717635
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (patient-controlled)
Study: 27717635
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 100μg and 150μg
Study: 27717635
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 50μg, 100μg, 150μg
Study: 20429647
Drug: L (laser)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L (laser)
Study: 20429647
Drug: C (no
Normalized name: SAPOSIN C (NON-GLYCOSYLATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (no treatment)
Study: 18480686
Drug: Methylphenidate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (10 mg PO twice a day)
Study: 16260821
Drug: Reality orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reality orientation therapy combined with donepezil
Study: 12905915
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine mouthrinse used twice daily for 21 days
Study: 12905915
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine mouthrinse used with routine daily brushing for 180 days
Study: 7495392
Drug: Ibopamine (IBO)
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (IBO) 100 mg
Study: 7495392
Drug: Captopril (CAP)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CAP) 25 mg
Study: 2114069
Drug: Oral ftorafur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ftorafur
Study: 18567279
Drug: Pycnogenol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (60 mg/day)
Study: 24667161
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate 1 g/day
Study: 24515912
Drug: Rehabilitation exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation exercise therapy combined with total glucosides form Shaoyao Gancao decoction
Study: 24515912
Drug: Rehabilitation exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation exercise therapy only (control group)
Study: 22926597
Drug: D-MPH-ER 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-MPH-ER 30 mg/day
Study: 22926597
Drug: D-MPH-ER 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-MPH-ER 20 mg/day
Study: 20479948
Drug: Amlodipine/Atorvastatin (AML/ATO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/Atorvastatin (AML/ATO) + Therapeutic Lifestyle Changes (TLC)
Study: 20479948
Drug: Amlodipine/Atorvastatin (AML/ATO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/Atorvastatin (AML/ATO) + TLC
Study: 12489899
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 mg in the first week, 200 mg in the second week)
Study: 10516393
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) administered at 12 and 24 hours of age
Study: 10516393
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no DEX treatment)
Study: 7793185
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg IM 6 hourly postoperatively
Study: 6366135
Drug: L-phenylalanine mustard
Normalized name: L-Phenylalanine mustard
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-phenylalanine mustard and 5-fluorouracil (PF) with tamoxifen (T)